Details for Patent: 10,151,763

Which drugs does patent 10,151,763 protect, and when does it expire?

Patent 10,151,763 protects KORLYM and is included in one NDA.

This patent has twelve patent family members in ten countries.

Summary for Patent: 10,151,763

Title:	Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome
Abstract:	Improved methods and systems for diagnosing and for treating Cushing's syndrome and Cushing's Disease are provided herein, including methods and systems for concurrently treating Cushing's syndrome and differentially diagnosing Cushing's Disease from Ectopic Cushing's Syndrome in a patient with an established diagnosis of ACTH-dependent Cushing's syndrome. Treatment methods can use glucocorticoid receptor antagonists (GRAs), which differentially affect the ratio of cortisol to ACTH levels in patients having Cushing's Disease versus patients having Ectopic Cushing's Syndrome. Methods for concurrently treating and differentially diagnosing Cushing's Disease from Ectopic Cushing's Syndrome include obtaining baseline cortisol and ACTH levels of a patient, treating the patient with a GRA according to a protocol that would typically substantially elevate cortisol levels, obtaining post-treatment cortisol and ACTH levels of the patient, determining a differential relationship between baseline cortisol and ACTH levels and post-treatment cortisol and ACTH levels and providing a positive diagnosis based on the differential relationship.
Inventor(s):	Moraitis; Andreas G. (Menlo Park, CA)
Assignee:	Corcept Therapeutics, Inc. (Menlo Park, CA)
Application Number:	15/627,414
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,151,763
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,151,763

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes						TREATING CUSHING'S SYNDROME

International Family Members for US Patent 10,151,763

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017210156
Canada	3011728
European Patent Office	3405101
Spain	2861524
Israel	260687
Japan	2019503495